13:15 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Noctiva regulatory update

FDA approved an NDA from Serenity for Noctiva desmopressin nasal spray to treat nocturia due to nocturnal polyuria in adults who awaken ≥2 times per night to urinate. Serenity also regained all rights to Noctiva...
23:22 , Nov 3, 2016 |  BC Week In Review  |  Company News

Ferring sales and marketing update

Ferring launched Noqdirna desmopressin in the U.K. to treat nocturia due to idiopathic nocturnal polyuria. The NHS list price of the freeze-dried formulation of a vasopressin analog is £15.16 ($18.46) for 30 tablets of 25...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

Desmopressin nasal spray regulatory update

FDA’s Bone, Reproductive and Urologic Drugs advisory committee voted 14-4 in favor of the risk-benefit profile of Serenity’s desmopressin nasal spray to treat nocturia in adults who awaken >=2 times per night to urinate. Serenity...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Voncento regulatory update

EMA’s CHMP recommended extending the indication of Voncento from CSL to include prophylaxis and treatment of hemorrhage or surgical bleeding in patients with von Willebrand disease (vWD) when desmopressin treatment alone is ineffective or contraindicated....
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Sanofi, Ferring deal

Ferring reacquired rights to desmopressin acetate (dDAVP) from Sanofi to treat nocturnal enuresis (bedwetting). The peptide-based synthetic analogue of vasopressin is available in tablet, nasal spray, rhinal tube and injectable formulations, all of which have...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

CSL sales and marketing update

CSL's CSL Behring subsidiary launched the My Access cost share program, which covers up to $12,000 in annual out-of-pocket costs of a CSL Behring therapy for hemophilia A or von Willebrand disease (vWD) for patients...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Alphanate update

Grifols launched the SPIRIT registry to evaluate Alphanate in 100 patients with hemophilia A and inhibitors. Alphanate is approved in the U.S. to treat hemophilia A, congenital von Willebrand disease (vWD) and for use in...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Humate-P regulatory update

EMA's CHMP issued a positive opinion recommending approval of Voncento from CSL's CSL Behring subsidiary to treat and prevent bleeding in patients with hemophilia A and von Willebrand disease (vWD). The product is recommended to...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Ferring, Kyowa Hakko Kirin sales and marketing update

Ferring and Kyowa launched Minirinmelt desmopressin in Japan to treat central diabetes insipidus. The product was approved for the indication on Dec. 25, 2012. The National Health Insurance (NHI) listing price of the peptide-based synthetic...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Company News

Ferring, Kyowa Hakko Kirin sales and marketing update

Ferring launched Minirinmelt desmopressin in Japan to treat nocturnal enuresis (bedwetting). The product was approved in Japan on March 30. The National Health Insurance (NHI) listing price of the peptide-base synthetic analogue of vasopressin is...